Challenges and future of biomarker tests in the era of precision oncology: Can we rely on immunohistochemistry (IHC) or fluorescence in situ hybridization (FISH) to select the optimal patients for matched therapy?

Molecular techniques have improved our understanding of the pathogenesis of cancer development. These techniques have also fueled the rational development of targeted drugs for patient populations stratified by their genetic characteristics. These novel methods have changed the classic paradigm of d...

Descripción completa

Detalles Bibliográficos
Autores principales: Chae, Young Kwang, Arya, Ayush, Chiec, Lauren, Shah, Hiral, Rosenberg, Ari, Patel, Sandip, Raparia, Kirtee, Choi, Jaehyuk, Wainwright, Derek A., Villaflor, Victoria, Cristofanilli, Massimo, Giles, Francis
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Impact Journals LLC 2017
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725070/
https://www.ncbi.nlm.nih.gov/pubmed/29246028
http://dx.doi.org/10.18632/oncotarget.19809

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725070/
https://www.ncbi.nlm.nih.gov/pubmed/29246028
http://dx.doi.org/10.18632/oncotarget.19809

Ejemplares similares